Everything You Need to Know About Zuclopenthixol

[smfadmin (OP)]

CLOPIXOL (Zuclopenthixol) — Harm Reduction & Drug Information

Thioxanthene Antipsychotic — Comprehensive Overview

1. OVERVIEW

Clopixol is the brand name for zuclopenthixol, a first-generation (typical) antipsychotic belonging to the thioxanthene class. It is used primarily in the management of schizophrenia, psychosis, and agitation associated with psychotic states. It is available in three distinct formulations with meaningfully different pharmacokinetic profiles.


2. FORMULATIONS

Clopixol Tablets (Zuclopenthixol dihydrochloride)

• Oral preparation; 2mg, 10mg, 25mg tablets
• Onset: ~2–4 hours
• Half-life: ~20 hours
• Duration: 12–24 hours per dose
• Used for maintenance and dose titration

Clopixol Acuphase (Zuclopenthixol acetate) — IM Injection

• Short-to-medium acting depot for acute agitation
  
• Onset: 2–4 hours post-injection
• Peak plasma: ~36 hours
• Duration: 48–72 hours per injection
  
• Dose range: 50–150mg IM (max 400mg per course)
• NOT a long-term depot — specifically designed for acute/emergency use

Clopixol Depot (Zuclopenthixol decanoate) — IM Injection

• Long-acting depot for maintenance therapy
• Onset: 24–48 hours
• Peak plasma: ~5–7 days
• Half-life: ~19 days
• Duration: 2–4 weeks per injection
  
• Typical dose: 200–400mg every 2–4 weeks
• Vehicle: thin vegetable oil (viscoleo)

3. MECHANISM OF ACTION

Zuclopenthixol is the cis (Z) isomer of clopenthixol. Its antipsychotic effects are primarily attributed to:

• D2 receptor antagonism — high affinity blockade in mesolimbic and mesocortical pathways (responsible for antipsychotic effect and EPS risk)
  
• D1 receptor antagonism — moderate affinity
  
• α1-adrenergic antagonism — contributes to sedation and hypotension
  
• H1 histamine antagonism — sedation
  
• Muscarinic (M1) antagonism — anticholinergic effects; moderate affinity
  
• 5-HT2A antagonism — moderate; partial attenuation of EPS
  

Unlike many atypical antipsychotics, zuclopenthixol has low serotonin-to-dopamine antagonism ratio, giving it a predominantly "typical" receptor profile with higher EPS liability.


4. PHARMACOKINETICS

Oral:

• Bioavailability: ~44% (first-pass effect)
• Protein binding: ~98%
• Vd: highly lipophilic; extensively distributed into CNS and adipose tissue
• Metabolism: hepatic; CYP2D6 (primary), CYP3A4 (minor)
• Metabolites: largely inactive
• Excretion: faecal (>85%), renal (~<15%)
• t½: ~20 hours (oral), ~19 days (decanoate depot)

Note for CYP2D6 poor metabolisers: plasma levels can be significantly elevated, increasing EPS and sedation risk.


5. CLINICAL USES

• Acute and chronic schizophrenia
• Acute psychosis and mania
• Agitation, aggression, and hostility in psychotic disorders
• Treatment-resistant patients requiring depot formulations for compliance
• Acute behavioural disturbance (Acuphase)

6. SIDE EFFECTS

Extrapyramidal Symptoms (EPS) — High risk

• Akathisia — subjective inner restlessness; may be severe and distressing
  
• Parkinsonism — tremor, rigidity, bradykinesia; dose-dependent
  
• Dystonia — acute muscle spasms (especially oculogyric crisis, torticollis)
  
• Tardive dyskinesia (TD) — potentially irreversible with long-term use; involuntary orofacial/limb movements
  

Metabolic

• Weight gain (moderate; less than olanzapine/clozapine)
• Hyperprolactinaemia — galactorrhoea, amenorrhoea, sexual dysfunction, gynaecomastia
• Glucose dysregulation (less prominent than SGAs)

Cardiovascular

• QTc prolongation — clinically significant; avoid with other QT-prolonging agents
• Orthostatic hypotension
• Tachycardia

Anticholinergic

• Dry mouth, constipation, urinary retention, blurred vision
• Cognitive blunting

Sedation & CNS

• Significant sedation — especially at initiation and with Acuphase
• Cognitive dulling
• Lowered seizure threshold

Rare but Serious

• Neuroleptic Malignant Syndrome (NMS) — hyperthermia, rigidity, autonomic instability, elevated CK; medical emergency
  
• Agranulocytosis (rare; more associated with clozapine but possible)

7. CONTRAINDICATIONS

• Comatose states or CNS depression
• Concomitant use of large doses of CNS depressants
• Known hypersensitivity to thioxanthenes
• Phaeochromocytoma
• Circulatory collapse
• Blood dyscrasias

Relative contraindications: Parkinson's disease, Lewy body dementia (severe dopaminergic sensitivity), prolonged QTc at baseline, hepatic impairment.


8. DRUG INTERACTIONS

• CNS depressants (benzodiazepines, opioids, alcohol, antihistamines) — additive sedation; respiratory depression risk
  
• QT-prolonging drugs (methadone, amiodarone, macrolides, many others) — synergistic QTc prolongation; potentially fatal arrhythmia
  
• CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion) — elevated zuclopenthixol plasma levels
  
• Anticholinergics — additive anticholinergic burden
  
• Metoclopramide, prochlorperazine — additive EPS risk
  
• Lithium — increased neurotoxicity risk; monitor levels
  
• Levodopa / dopamine agonists — mutual antagonism; avoid
  
• Stimulants (amphetamines) — D2 antagonism blunts dopaminergic effects of stimulants; may precipitate or worsen dysphoria/akathisia
  

9. HARM REDUCTION NOTES

⚠ Acuphase Caution
Acuphase is sometimes misused as a "chemical restraint" or given without full informed consent in inpatient settings. Be aware:

• Its effects last 48–72 hours — you may feel sedated and cognitively impaired for days
• You have the right to refuse or request alternatives in most jurisdictions (unless legally involuntary)
• It should not be confused with the long-acting depot — doses and durations differ significantly
  

⚠ EPS Management

• Benztropine or biperiden can manage acute dystonia and Parkinsonism
• Propranolol is first-line for akathisia; benzodiazepines second-line
• Tardive dyskinesia has no reliable treatment — prevention through lowest effective dose and regular monitoring is critical
• Vitamin B6 (pyridoxine) has some evidence for TD and akathisia

⚠ Stimulant Use
If you use amphetamines or other dopaminergic stimulants alongside Clopixol:

• D2 blockade substantially attenuates stimulant effects and euphoria
• Pushing stimulant doses higher to "overcome" blockade increases cardiovascular risk and dysphoria without proportional reward
• Hyperprolactinaemia combined with stimulant-driven catecholamine release can produce unpredictable cardiovascular effects
• QTc risk from Clopixol is compounded by stimulant-induced tachycardia

⚠ Depot Discontinuation

• Depot formulations cannot be rapidly reversed — if adverse effects emerge, they persist for the full injection window
• Tardive dyskinesia and tremor may persist long after depot cessation due to slow clearance
  
• Taper guidance should be supervised; abrupt psychiatric decompensation is possible

10. MONITORING RECOMMENDATIONS

• ECG — baseline and periodically (QTc monitoring)
• FBC — blood dyscrasias
• LFTs — hepatic metabolism
• Fasting glucose & lipids — metabolic monitoring
• Prolactin — if symptomatic
• Movement disorder assessment (AIMS scale) — for tardive dyskinesia
• Blood pressure — particularly postural

11. COMPARISON WITH RELATED DRUGS

[th]Drug[/th][th]Class[/th][th]EPS Risk[/th][th]Sedation[/th][th]Metabolic Risk[/th][th]Depot Available[/th]
Zuclopenthixol (Clopixol)	Thioxanthene (FGA)	High	High	Moderate	Yes
Haloperidol	Butyrophenone (FGA)	Very High	Low	Low	Yes
Flupenthixol (Fluanxol)	Thioxanthene (FGA)	High	Low–Moderate	Moderate	Yes
Olanzapine	Thienobenzodiazepine (SGA)	Low	High	Very High	Yes
Risperidone	Benzisoxazole (SGA)	Moderate	Moderate	Moderate	Yes
Clozapine	Dibenzodiazepine (SGA)	Very Low	Very High	Very High	No

12. LEGAL & SCHEDULING STATUS

• Australia: Schedule 4 (Prescription Only Medicine) — PBS listed for schizophrenia
  
• UK: Prescription Only Medicine (POM)
  
• EU: Prescription required; widely available in European markets
  
• USA: Not FDA-approved or commercially available
  

This information is provided for harm reduction and educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare professional regarding your medications. If you are experiencing a medical emergency, contact emergency services immediately.

Generated by AI

[Chip]

I was on it but it gave me hand tremors so I stopped it cold turkey - it fixed my problem before it became permanent !